MARKET

TNFA

TNFA

TNF Pharmaceuticals
NASDAQ
0.1960
+0.0060
+3.16%
Pre Market: 0.1897 -0.0063 -3.21% 06:50 05/13 EDT
OPEN
0.1888
PREV CLOSE
0.1900
HIGH
0.2000
LOW
0.1753
VOLUME
2.60K
TURNOVER
--
52 WEEK HIGH
2.600
52 WEEK LOW
0.1615
MARKET CAP
1.99M
P/E (TTM)
-0.0176
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at TNFA last week (0505-0509)?
Weekly Report · 22h ago
TNF Pharmaceuticals Amends Bylaws to Alter Voting Rules
TipRanks · 3d ago
TNF Pharmaceuticals And Renova Health Announce Initial Results From AI-Driven Study Of 30K Patients On GLP-1 Agonists, Highlighting Potential Of Isomyosamine To Improve Diagnosis, Preserve Muscle Mass, And Enhance Treatment For Inflammatory Conditions
Benzinga · 4d ago
TNF PHARMACEUTICALS AND RENOVA HEALTH REPORT POSITIVE RESULTS IN IDENTIFYING TARGETS FOR TREATING TNF-DRIVEN INFLAMMATION IN PATIENTS RECEIVING GLP-1 AGONISTS
Reuters · 4d ago
Weekly Report: what happened at TNFA last week (0428-0502)?
Weekly Report · 05/05 12:17
Weekly Report: what happened at TNFA last week (0421-0425)?
Weekly Report · 04/28 12:31
TNF Pharmaceuticals, Renova Health partner using AI for drug development
TipRanks · 04/22 13:36
TNF Pharma and Renova Health Partnership Utilize AI To Accelerate Isomyosamine Drug Development
Benzinga · 04/22 13:17
More
About TNFA
More
TNF Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company, which is engaged in developing novel oral therapies for autoimmune and inflammatory conditions. It is focused on developing and commercializing two therapeutic platforms based on well-defined therapeutic targets: MYMD-1 and Supera-CBD. MYMD-1 is a clinical-stage small molecule that is being developed to treat age-related illnesses such as frailty and sarcopenia. MYMD-1 works by regulating the release of numerous pro-inflammatory cytokines, such as TNF-a, interleukin 6 (IL-6) and interleukin 17 (IL-17). MYMD-1 can also treat autoimmune diseases, including (but not limited to) multiple sclerosis, diabetes, rheumatoid arthritis, and inflammatory bowel disease. Supera-CBD is a synthetic analog of cannabidiol (CBD) being developed to treat various conditions, including, but not limited to, epilepsy, pain, and anxiety/depression, through its effects on the CB2 receptor, and a monoamine oxidase enzyme (MAO) type B.
Recently
Symbol
Price
%Change

Webull offers TNF Pharmaceuticals Inc stock information, including NASDAQ: TNFA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TNFA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading TNFA stock methods without spending real money on the virtual paper trading platform.